The dual role of baseline absolute eosinophil count in non-small cell lung cancer immunotherapy: a biomarker for enhanced efficacy and elevated risk of immune checkpoint inhibitor-related pneumonitis
本文未提供摘要，请点击“查看全文”查看完整内容。